---
title: "Shanxi C&Y Pharmaceutical Group Co., Ltd. (300254.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/300254.SZ.md"
symbol: "300254.SZ"
name: "Shanxi C&Y Pharmaceutical Group Co., Ltd."
industry: "Pharmaceuticals"
datetime: "2026-05-20T19:24:02.776Z"
locales:
  - [en](https://longbridge.com/en/quote/300254.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/300254.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/300254.SZ.md)
---

# Shanxi C&Y Pharmaceutical Group Co., Ltd. (300254.SZ)

## Company Overview

ShanXi C&Y Pharmaceutical Group Co.,LTD. engages in the research, development, production, and sale of medicine and health food products. It provides anti-infective drugs, anti-allergic drugs, respiratory drugs, urinary system drugs, kidney disease drugs, children's drugs, cardiovascular and cerebrovascular drugs, anti-depressants, medicines, pharmaceutical raw materials, and intermediates, commerce, etc. The company’s product portfolio includes Fosfomycin tromethamine powder, Ebastine tablets, Tamsulosin hydrochloride sustained release capsules, Cinacalcet hydrochloride tablets, Apixaban tablets, Rivaroxaban tablets, Fluoxetine hydrochloride capsules, Ambroxol hydrochloride dispersible tablets, Montmorillonite powder, Varenicline tartrate tablets, Vitamin AD drops, and Baoling Yunbao oral liquid, as well as salt acid glucosamine raw material product.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.cy-pharm.com](https://www.cy-pharm.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:11.000Z

**Overall: C (0.50)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 0 / 215 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 0.00% |  |
| Net Profit YoY | 0.00% |  |
| P/B Ratio | 8.13 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 3583500800.42 |  |
| Revenue | 850774526.45 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 4.32% | C |
| Profit Margin | 2.40% | C |
| Gross Margin | 65.60% | A |
| Revenue YoY | 1.56% | C |
| Net Profit YoY | -75.48% | E |
| Total Assets YoY | 1.49% | C |
| Net Assets YoY | -32.30% | E |
| Cash Flow Margin | 408.95% | A |
| OCF YoY | 1.56% | C |
| Turnover | 0.55 | C |
| Gearing Ratio | 62.76% | D |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Shanxi C&Y Pharmaceutical Group Co., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "0.00%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "0.00%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "8.13",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "3583500800.42",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "850774526.45",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "4.32%",
          "rating": "C"
        },
        {
          "name": "Profit Margin",
          "value": "2.40%",
          "rating": "C"
        },
        {
          "name": "Gross Margin",
          "value": "65.60%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "1.56%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "-75.48%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "1.49%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "-32.30%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "408.95%",
          "rating": "A"
        },
        {
          "name": "OCF YoY",
          "value": "1.56%",
          "rating": "C"
        },
        {
          "name": "Turnover",
          "value": "0.55",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "62.76%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 188.85 | 156/215 | 204.96 | 139.09 | 86.74 |
| PB | 7.64 | 205/215 | 10.63 | 9.72 | 9.10 |
| PS (TTM) | 3.90 | 107/215 | 3.60 | 3.34 | 3.12 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Allist (688578.SH) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | A | B | A |
| 03 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 05 | Haisco (002653.SZ) | A | A | B | B | B | B |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/300254.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/300254.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/300254.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/300254.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**